Orphan drug designation (ODD) application

The application dossier for the Orphan Drug Designation for the cell therapy developed by Hemera was sent to EMA, the European Medicine Agency. This designation will give access to important concessions, accelerating the authorization process, reducing its costs, and allowing clinical trials on small groups of patients.

Strategic partnership with Miltenyi Biotech Italia

Hemera signed a Strategic Collaboration Agreement with Miltenyi Biotech Italia. Miltenyi is a German multinational company, world market leader for scientific instrumentation for cell isolation, culture, and analysis. The Hemera-Miltenyi collaboration provides scientific-technological support for the setting and customization of cell therapy production equipment for research and clinical use.

Presentation of Hemera at the conference on advanced therapies

Hemera was invited to the conference “Advanced therapies: clinical practice, new perspectives, rules for quality”, a highly valuable scientific environment with a focus on the latest cell therapies, intended for a qualified audience of scientists and experts in cell therapies and regulatory processes.

Professor Bifari, Director of Therapy Development at Hemera, gave a lecture entitled “Development of a novel cell therapy for the treatment of spinal injuries,” presenting the promising preclinical research data of the REMAST cell therapy for the treatment of spinal injury.

Aumento di capitaleCapital increase

With the 6^th capital increase in 18 months, Hemera has raised a total of 2,125,000 euros, thanks to the generosity and social responsibility of over 150 private investors, business angels, and family offices, who have decided to invest in our extraordinary scientific and entrepreneurial project. Our investors have organized themselves into the two investment syndicates: Friends of Founders S.r.l. and Proemera S.r.l.. The raising of capital continues in 2023 with the target of 2.5 million.